Alliance milestone and obligation tracking, explained.

A first dose in Lyon and the milestone promised three years earlier

How one milestone gets from a signed license to a payment

1. The deal is signedNorthwind Bio licenses Talvoren from Quillon Therapeutics. The license lists five milestones, each with an amount and a notice term.
2. The terms changeAmendment No. 1 raises one milestone and shortens its notice. The first agreement stays in the file, looking just as official.
3. Something happens outside the contractThe first patient in the Phase 3 trial is dosed in Lyon. The clock starts on that day, whether or not the alliance team knows.
4. The event is tested against the wordsSomeone checks each defined term against the evidence, applies the amendment and counts the days. A person decides the milestone is achieved.
5. Notice, accrual, paymentCounsel signs the notice, finance records the expense in the right month, and the partner's invoice is paid on its own term.

This guide is about step 4. The companies, dates and amounts in this example are fictional.

What surprises people new to license obligations

Milestone, defined term, notice clock, steering committee: the words a license turns on

Six families of license obligations, from milestone payments to option windows and sublicense consents

In shortAn obligations register holds much more than milestones. Payments, reports, committee meetings, diligence targets, consents and rights all carry clocks. A useful register records who owes each one, what starts its clock and which clause it comes from, in the wording in force.

Teams tend to start with the big payments that wait on events, because those are the numbers leadership knows. The everyday risk sits in the rest of the list. The table below groups the common duties into six families. The examples come from this guide's fictional alliance book, meaning all the agreements one company holds with its partners, and the clause wording in that book is sample text. Your agreements will carry their own numbers, and you may split or merge these families.

Direction matters as much as type. In the sample book Northwind owes Quillon a milestone, while Marrow Point Bio owes Northwind a royalty report and a monthly supply forecast. A register that only lists what you owe will miss a late forecast from a partner, and a register that only lists dated items will miss duties that wait for an event, such as a 30-day notice before a partner abandons a licensed patent.

No public figure gives the number of obligations in a typical biopharma license. The sample book here has 612 across 38 agreements, about 16 per agreement. Count one of your own agreements to see how your number compares.

Why biopharma deal value sits in milestones: upfront cash at 6% of $221 billion in announced licensing

In shortLicensing is large and milestone-heavy. J.P. Morgan reports $221.1 billion of announced R&D licensing value through the third quarter of 2026, with upfront cash at 6%. The rest depends on events, so tracking events is tracking money.

Announced value overstates what will ever be paid, since it adds up every milestone as if all of them will happen. It still tells you where the contract's weight sits.

Goodwin's review of more than 200 licensing and collaboration deals in 2025 found that for early-stage deals, upfront payments rose from 1.5% to 3.7% of overall value, median development milestones rose from 23% to 33%, and commercial milestones fell from 73% to 64%.6 So in those deals a larger share of the value now depends on development events, the kind that happen in trial systems and regulators' offices.

Royalties, a percentage of sales paid to the licensor, sit beside milestones. Goodwin's 2025 medians run from a low tier of 4.5% to a high tier of 8% for early-stage deals, and from 9.3% to 13% for later-stage ones.6 Each royalty brings its own quarterly report, payment date and audit right, which is how a single license ends up holding dozens of obligations.

Cross-border licensing adds partners who announce news in other languages and time zones

Those same China-origin deals received 65% of the upfront dollars in that group this year, according to the report.4 For an alliance team, that means more events announced far from head office, in another language and on another working calendar. A partner's press release at 7:30 in the morning in Asia is yesterday evening in New York.

We could not verify a published market size for alliance tracking software, so this guide gives none. What you can measure is your own open contingent value: the total of every milestone on your book that has yet to happen, owed and owing. That total is the money your tracking looks after.

What "Initiation of a Phase 3 Clinical Trial" means depends on your contract's definitions section

In shortA milestone is a chain of defined terms, and filed agreements define the same event differently: first dosing in one, first patient enrolled in another. Test each term against evidence and you know whether the milestone happened. Assume, and you may pay in the wrong quarter or not at all.

Read one milestone slowly. "Initiation of the first Phase 3 Clinical Trial of a Licensed Product" has four separate tests inside it: what counts as initiation, what counts as a Phase 3 trial, what counts as a Licensed Product, and whether this is the first time. Each capitalized term points to its own definition, often 40 or 50 pages from the milestone table.

Three filed licenses, three ways to say a Phase 3 trial started

Those are real filings, read as filed, and some amounts are redacted. They show the range. The date of a first dose and the date of a first enrollment can sit in different months. Here is how that plays out on an illustrative trial, where enrollment falls in the third quarter and the first dose in the fourth.

Six tests behind one milestone, worked on the sample license

Take the Quillon license from the example. To say Milestone 4, the first Phase 3 start, has been achieved, someone has to establish six things. Each one has its evidence, and two of them changed by amendment.

"Phase 3" deserves a second look. FDA's regulation describes Phase 3 studies as expanded controlled and uncontrolled trials, performed after preliminary evidence of effectiveness, intended to gather the further information needed to evaluate overall benefit and risk and to provide a basis for labeling, usually with several hundred to several thousand subjects.7

A contract may borrow that language, add its own, or define the phase by its purpose. A combined Phase 2/3 study, a trial in a second indication or a study run by a sublicensee in another country can each raise a real question under the words. Those are questions for counsel, and the tracker's job is to put them in front of counsel in time.

Regulatory dates need the same care. FDA decides within 60 days of receiving an application whether it can be filed, and the filing date is day 60.8 So "acceptance for filing" and "submission" are about two months apart, and a milestone on one can land in a different quarter from a milestone on the other.

Counting a license notice clock: ten business days, a bank holiday and the date 30 days would have given

In shortEach clock has a start, a unit and a calendar. On the sample license the old term read November 4, and the amended term, counted on New York bank days with Columbus Day skipped, reads October 20. Date arithmetic is easy; finding the right start, unit and calendar is where teams slip.

The sample license says a Business Day is a day banks are open in New York. The first dose was on Monday, October 5, 2026. Federal Reserve Banks close on Columbus Day, October 12, 2026, so that day does not count.9 Counting begins the next day.

The same book holds clocks of many shapes. Each row below is a sample term worked through, so you can see the three questions at work: when does it start, in what unit, and on what calendar.

A last trap is form. The notice clause usually says who receives the letter, in which role and how it travels. In the sample it goes by courier and email to a named officer with a copy to the general counsel. An email to your usual contact at the partner, however friendly, may not count as notice under the words.

Where milestone events first appear: trial systems, public registries, regulators' goal dates and partners' press releases

In shortEach trigger has a first witness, usually a system that the alliance team does not read. Public registries are independent and late by design: US rules allow 21 days after first enrollment to register and 30 days to update status. Your own trial system knows first, and a partner's press release may be the only warning of a partner's act.

So a registry works as an independent check that arrives late. In the US the party responsible for the trial must register an applicable clinical trial no later than 21 calendar days after the first human subject is enrolled, and must update overall recruitment status within 30 calendar days of a change.10,11 If nobody was enrolled at registration, the study start date must be updated within 30 calendar days of first enrollment.11

In the EU the sponsor notifies each member state of the first visit of the first subject within 15 days, through the EU portal.12 None of those records shows one subject's first dose. They show status and dates, so a definition built on first dose still needs the trial record.

Regulators' dates: how a goal date is worked out

Regulatory milestones have their own arithmetic. Under the current FDA user fee goals, the review targets tied to the fees drug companies pay, the agency aims to act on 90% of standard new molecular entity applications (drugs with a new active ingredient) and original biologics applications within 10 months of the 60-day filing date, and 90% of priority ones within 6 months of it.13 So a standard original application submitted in mid-November has a goal date, the day FDA aims to act by, about 12 months later.

These are performance goals. FDA can act earlier or later, or decline to approve, and a contract clock usually starts on the action itself.

A partner's acts are the hardest events to see. When a licensee grants a sublicense, sells itself or starts a study you are entitled to hear about, the first you may learn of it is a press release, and most press releases mention no clause. Reading that release against your agreement is the work that protects a consent right.

Volume is the second problem. Anyone who has set a news alert knows most hits lead nowhere. An event can match a clause and still trigger nothing: a partner finishing enrollment does not earn a milestone that pays on approval. A workable process records those decisions as well, with the reason, so the next person does not check the same event again.

Amendments, sublicense consents and change of control, and what changed for licenses in 2026

In shortThe wording in force is a stack: agreement, amendments, side letters (short signed add-ons), committee decisions. Consent rights are enforced only by someone who notices. In 2026 the EU replaced its technology transfer block exemption, US agencies were still considering collaboration guidance, and US measures on biotechnology suppliers and outbound investment moved forward.

Finding the wording in force

Amendments can replace a whole section. One filed amendment deletes the milestone section "in its entirety" and writes a new schedule, four years after the license was signed.2

After that, the original PDF is wrong about the money, yet it remains the longest and most official document in the folder. So each line in a register needs the clause in force, the document that changed it, its effective date and the replaced wording kept for the record, because a dispute may ask what was owed on a date in the past.

Committee minutes are the awkward case. Some agreements let a committee set rates or approve changes, and others say a committee cannot amend the agreement at all. Whichever yours says, write it down for each agreement and have counsel check any minute that looks like it changes a term.

Sublicense consent and change of control

Many licenses forbid sublicensing without consent. The sample one adds that a sublicense granted in breach is void, and draws a line between a sublicensee and a distributor who simply buys and resells. Which side of the line a deal falls on is a legal judgment that turns on rights: who holds the marketing authorization, who may develop, who may make the product.

Change of control, when a partner is bought or merged, raises a related question. In Meso Scale v. Roche, a Delaware court held in 2013 that a reverse triangular merger, in which the target survives as a subsidiary, was not an assignment "by operation of law or otherwise", so an anti-assignment clause did not reach it.14 The court declined to follow a 1991 California-law decision that went the other way, and commentators advise parties who want a different result to write a change-of-control clause.15

For a tracker the lesson is modest: a partner's merger announcement should prompt someone to read the assignment and change-of-control clauses that same week.

Clean teams when partners co-promote, with US collaboration guidelines withdrawn

When partners co-promote, selling one medicine together, they may swap information that competitors should not share, such as net prices. A clean team, a small named group walled off from pricing decisions, is one common answer, often set out in a side letter.

US agencies withdrew their 2000 collaboration guidelines on December 11, 2024,16 after withdrawing information-sharing safe harbors in 2023.17 On February 23, 2026 they asked for comment on reintroducing guidance built on the old guidelines,18 and we found none as of November 3, 2026. The FTC's guide on dealings with competitors, read that day, lists no new guidelines;19 we could not read a matching Justice Department page.

FTC staff wrote in 2018 that merger parties should use clean teams, and that they "should not include any personnel responsible for competitive planning, pricing, or strategy".20 That post concerns pre-merger due diligence. We found no agency text on clean teams in a co-promotion, so yours rests on counsel's advice, and your tracker should keep restricted data out of the wider alliance view.

The EU change carries a date. Regulation (EU) 2026/877, the EU's new competition-law exemption for technology licenses, entered into force on May 1, 2026. Its market share thresholds are 20% combined for competing parties and 30% each for non-competitors. An agreement in force on April 30, 2026 that met the old rule but not the new one has until April 30, 2027 to be brought into line.21 Check your European licenses against it. That is a one-time job with a deadline, the kind of item that belongs in the register.

Milestone payments accounting: when the payer accrues, when the licensor recognizes revenue, and why the date matters

In shortThe two sides of one milestone follow different rules. A US payer buying rights to an unapproved drug generally expenses the payment as research and development. A licensor treats it as variable consideration, often zero until the event. Finance needs the achievement date and the evidence in the month it happens.

A few words first. An accrual is an amount recorded as owed before it is paid. The licensor grants the rights and the payer took them. ASC numbers are sections of the US accounting rulebook, known as US GAAP, and IFRS is the international set.

A $40 million entry, worked through

On the sample license, the first dose falls on October 5, so a US payer records research and development expense of $40,000,000 and an accrued liability of $40,000,000 in the October close. Payment follows 45 days after the partner's invoice.

Suppose the definition had paid on enrollment instead, on the illustrative September 28 date from section 4. The same $40 million would belong in the third quarter, in numbers the company may already have closed. Read the definition, then read the date. Your accounting policy decides the entry, and your auditors will ask to see the evidence.

Contingent values, and what a milestone is worth before it happens

Many milestones never get paid, because many programs stop. One widely used public dataset, BIO's study of 12,728 phase transitions from 2011 to 2020, found 52.0% of programs advance from Phase 1, 28.9% from Phase 2, 57.8% from Phase 3 and 90.6% from a filing to approval, or 7.9% from Phase 1 all the way.27 Rates vary widely by disease and type of drug.

Those expected values, amount times odds, are one reason finance wants news early. The other is disclosure: a large payment that has become probable may need to appear in a forecast or in a filing before it is paid. The sample book's open contingent value is $165 million in the coming quarter alone. Numbers like that belong in front of the controller well before the event.

The eight errors behind missed license obligations, and the habit that catches each

In shortOne published survey blames day-to-day execution for the largest share of alliance shortfalls. We found no public count of missed notices or lapsed options, so measure your own. The common errors share one root: the clause, the event and the owner live in different places.

Vantage Partners' survey of biopharma partnering professionals, as reported by the Association of Strategic Alliance Professionals in June 2024, found 66% of partnerships failing to reach the full value they set out to achieve, with about 56% of those partly successful. It attributed 48% of the shortfall to partnership execution.28

BDO's study, on data gathered in 2021 and 2022 from 183 alliance and account professionals across 11 industries, says more than half of partnerships fail to fully achieve their objectives.29 Both are surveys of practitioners, the first describing self-reported results, and neither isolates missed obligations. They tell you execution matters, which is as far as public data goes.

A central alliance function reported better results, on self-reported data

A central function can keep one register, one set of definitions and one review routine. The same survey says organizations that manage ongoing execution well are four times more likely to see success from partner programs.28 Treat those as signposts. Your own measure is simpler: of the dated obligations due in the last 12 months, how many did you meet on time, and how many did you only learn about afterward?

Milestone disputes and commercially reasonable efforts: what Delaware courts ordered from 2024 to 2026

In shortThe milestone disputes we found in public court records concern acquisitions. They turn on defined criteria and on efforts clauses, the promises to try that a contract measures in its own words, and they can reach hundreds of millions of dollars. Biopharma earnouts, later payments to a company's sellers, have paid about 19 cents on the dollar of what fell due, and one study ties $12.1 billion of missed payments to Phase III outcomes.

SRS Acquiom's 2025 study covers 466 private-target life sciences deals, 342 of them with an earnout.31 BioSpace's report on it gives $95.1 billion in potential payments across those 342 and $9 billion paid, counting milestones not yet due, with $12.1 billion in missed payments tied to Phase III outcomes against $1.5 billion paid for those events. Earnout disputes rose to 31% from 28% two years earlier.30

These are acquisitions, and licenses publish nothing comparable. Read them as a sign of how much money waits on events, and how often the parties end up disagreeing.

Two recent Delaware rulings, for what the records say

Three things follow for anyone keeping a register. First, the wording decides: outcomes turned on each contract's own efforts definition, and the Alexion contract measured efforts against a similarly situated company.32,35 Second, a milestone's criteria deserve the same care as its amount: the Alexion dispute over $130 million came down to whether study data met two criteria on an exhibit.32

Third, efforts are proved with a record: annual reports, committee minutes and the reasons for decisions are what a court reads years later, so a register that holds those with their dates is doing legal work as well as administrative work.

These cases are real and cited for what the records say. They have nothing to do with the fictional partners in this guide.

Reading licenses with AI: what it does well, how often it errs, and which rules reach alliance work

In shortAI can read long agreements, match events to clauses and draft letters. It also misses and invents things, at measured rates. Drug regulators' AI rules mostly stop short of contract work, so financial reporting controls and legal review are the rules that bite. A person decides, and every statement should open its source.

Which rules reach this work, and which stop short

So the sensible design follows from the evidence. Use software for reading, matching and counting, where it is fast and where a wrong answer can be checked against a quoted clause. Keep decisions with named people. Make every claim open its source, because a tool that misses a clause or invents one can only be caught by someone who can see the passage. And measure it on your own agreements: published benchmarks test clause finding on general commercial contracts, and none we found tests milestone definitions in biopharma licenses.

An alliance manager, a hand-built tracker and news that arrives late: how milestones are tracked today

In shortAn alliance manager usually owns a tracker, built by hand from the contracts, and hears about events from program teams and committee meetings. We found no public survey of hours or elapsed days, so the split below is an estimate for you to replace.

Six roles that each hold a piece of every milestone

About 15 business days on one hand-tracked milestone, most of them waiting for news

What a spreadsheet, contract software, alliance software and outside counsel each do for a register

One cross-industry reference point: World Commerce & Contracting says poor contract management erodes 8.6% of annual value,47 from research updated with Deloitte in 2022 across more than 1,200 organizations, with the best near 3% and the worst above 20%.48 A Deloitte article also says contract data in large organizations sits in 24 different systems on average, without naming the research.48 Neither figure is specific to biopharma, and neither measures alliances.

From a line on the alliance network to six tests on a $40 million milestone

In shortThis is the example from the top of the page, inside the product. The trial system reports a first dose. AI agents, software that each does one defined job, match it to four clauses, test six conditions and apply the amendment. Dana Okafor, the alliance director, sees "$40M · flagged" on her network the next morning and opens the evidence. On the sample book, event to tested trigger took 4 minutes.

1

The whole alliance book, drawn as one network

Wednesday, October 7, 2026. Northwind Bio sits in the center with its 8 active partners around it: 38 agreements, 612 obligations and 37 open lines. Each line is one obligation drawn from its clause, colored by kind, with an arrow for who owes whom and dashes when the payment is contingent. Three labels stand out: "$40M · flagged" on Quillon, "No consent on file" on Marrow Point and "$15M option · Nov 18" on Brightwater. The panel below quotes the clause in force.

2

An event read against every clause in the book

On October 6 at 4:20 pm, trial system event 88214 arrives: first dose in TLX-301, subject 114-001, Lyon, October 5. The signal watcher, the agent that reads outside events, searches 612 obligations and matches 4 clauses in the Quillon license: §7.2(d), §7.4, §7.6 and §5.2(b). Replaying the match lights each step in turn, from event read to milestone flagged, and the partner's lines list below the map.

3

Six conditions, each one click from its passage

The trigger checker splits Milestone 4 into its elements and tests each against numbered evidence: the license definitions, the trial record, the protocol title page and the payment register. Four conditions are met as written. Two are met on amended terms and marked so. The screen says "6 of 6 conditions met" and leaves the conclusion to Dana. On the left, the agent trace shows who did what and how long it took.

4

$40 million and October 20, from the wording in force

One click on "Amendment No. 1 §3" opens the signed amendment with the sentence highlighted: the words "within thirty (30) days" are replaced by "within ten (10) Business Days". Another click opens the count on the New York bank calendar the agreement names. The first dose was October 5, Columbus Day falls on October 12 and is not counted, and the tenth Business Day is Tuesday, October 20. Thirty days would have read November 4. The superseded wording stays on file, marked.

5

The alliance director decides whether it happened

Dana's choices are to confirm, ask counsel first, or record it as not achieved with a reason. The card says what confirming does: it records October 5 as the achievement date, starts the notice clock and the payment term, and drafts the notice, the October accrual and the owner tasks. It also notes that the diligence target in §5.2(b) is met, because France counts as a major EU country. Nothing is sent until counsel signs.

Milestone notice to accrual: thirteen days inside the clock, and the $40 million in the October close

In shortOnce Dana confirms, agents draft the notice from the clauses, and the accrual with its evidence attached. Licensing counsel signs. Above $10 million the controller approves before finance posts. In the sample, the notice goes out on October 7, thirteen days ahead of its October 20 date.

1

A draft notice built from the clauses it cites

The letter is addressed from §15.2, to Quillon's Chief Business Officer with a copy to General Counsel. It states the event, the date, Study TLX-301, US$40,000,000 and the 45-day payment term in §7.6. Every statement carries a numbered citation, so Omar Haddad, licensing counsel, can open the source of any sentence before he signs.

2

Counsel signs with the meaning of his signature

The signature dialog says Omar signs as Licensing Counsel, with the meaning "I approve this notice for sending". Name, time and meaning are recorded with the document. Delivery follows the notice clause: courier and email. Afterward the notice reads as signed and sent on October 7, with a copy filed to the agreement.

3

The accrual lands in the month of achievement

The finance link, the agent that turns decisions into entries, drafts research and development expense against accrued liabilities, $40,000,000 each way, for October 2026. It attaches the clause as amended, trial system event 88214, the protocol and the payment register. Over $10 million, the controller approves before Sam Patel in business development finance posts. The entry itself follows your accounting policy, which is yours to set.

4

Owners and dates for what comes next

Four tasks follow, each with an owner and a date: sign and send the notice, post the accrual by October 31, pay Quillon within 45 days of its invoice, and update the steering committee by December 15. The diligence obligation is marked met, with the evidence beside it.

A sublicense nobody asked about, an option closing and five events set aside with a reason

In shortIn the same week the watcher raises a partner's Singapore sublicense with no consent on file, an option window closing November 18, and a detailing forecast under 90%. Events that match a clause but trigger nothing are set aside with the reason, and nobody is alerted.

1

The Marrow Point sublicense question goes to counsel

News watch matches a press release at 8:05 am on October 7: Jadeport Pharma receives an exclusive sublicense for Dravenzo in Singapore. The tests read the territory (§2.1), the sublicensing clause (§4.3), the distributor carve-out (§4.4) and the consent register, which holds no request. Whether this is a sublicense or a distributor is marked "Judgment" for Omar, with a suggested letter that asks for the terms within 10 days and reserves rights. All of it is fictional, and it describes no real company.

2

The option window, counted from acceptance

Brightwater delivered its data package on August 6 and Northwind accepted it on August 20. The 90-day option runs from acceptance, so it closes on November 18, and a $15,000,000 fee follows if Northwind exercises. If it does nothing, the option lapses and rights revert. Dana can put it on the October 28 portfolio committee, prepare an exercise notice or let it lapse on the record.

3

An event that triggers nothing is set aside with its reason

A registry shows Dravenzo's China Phase 3 completing enrollment. It matches a clause, and the clause pays on approval by China's regulator, so the screen says: no payment, §5.2(b) pays US$25,000,000 on NMPA approval. It is filed with its reason and nobody is alerted. A second example watches a VR-7 antibody study posted to a registry, because the milestone pays when the IND, the application to start human trials, becomes effective, and posting a study does not trigger it.

4

Aubrelle's detailing and Pellmore's approval: watching ahead

A detail is a sales representative's product visit to a prescriber. Aubrelle Pharma committed to 18,000 a year in Europe and delivered 11,940 to September 30. At the third-quarter rate of 1,210 a month that gives 15,570, or 86.5%, under the 90% line in §10.5. Co-promotion data comes in as aggregate counts only, so no prices leave the clean team.

Separately, the PLB-101 approval has an FDA goal date of November 18: if it comes, a $150,000,000 payment and a 5-Business-Day notice start together, and both are prepared and waiting.

One obligations register in both directions, clauses in force and the money calendar

In shortBehind the network sit the working screens: every event read, every obligation with its owner and clock, each agreement with amendments applied, and a dashboard of what you owe and are owed. Lead times, sources and signers are settings.

The solution's design targets: one day from a first patient dosed to a tested milestone ready to confirm, and 96.5% of obligations met by their contractual date over twelve months. These are design targets measured in the live solution. The screens show a sample book.

Who may do what: six agents read and draft, and named people confirm, sign and post

In shortEach agent has one job and a line it does not cross. No milestone is marked achieved, no notice sent and no large accrual posted without a named person, and every match, set-aside, decision and signature is on the audit trail.

The sample book's sign-offs: confirm, sign, post, approve above $10 million

The four-eyes rule means a second person signs what the first decided. Dana Okafor confirms each achievement. Omar Haddad signs each notice and consent letter, with his name, the time and the meaning of the signature recorded. Sam Patel posts accruals, and the controller approves any above the $10 million sample threshold.

Alliance managers Lena Ortiz and Priya Ranvelle verify what was extracted for their partners and see only those partners. Dr. Maya Chen, the program lead, owns diligence duties and trial facts. Each of these is a setting, so yours can differ.

What goes in, and what comes out of an alliance obligations register

Contract repository, trial system, ERP: what the solution connects to

The solution works with what you already have: your contract repository, trial management system, public trial registries, regulatory tracker, a news feed, ERP, CRM, a portfolio system and your electronic signature tool. Enterprise needs are built in: roles and separation of duties, maker-checker on each decision, an immutable audit trail you can export, partner-level access so each alliance manager sees only their own alliances, clean-team handling of co-promotion data, and agreements read in full at the scale of a large alliance book. Botminds is SOC 2 Type II audited, with information security managed to ISO 27001. Where your records fall under GxP (the good-practice quality rules for drug development and manufacturing) or 21 CFR Part 11, its controls support your compliance. That remains your responsibility, as your own validation does.

The price of a late notice, a lapsed option or a wrong-quarter accrual

In shortNobody publishes how often notices are missed or options lapse, so the cost case has to come from your own book. The published numbers show how much value rests on events, and how large disputes can grow. Start by re-checking one year of your own dated obligations.

Price your own misses from last year's dated obligations

What a missed clock costs that never shows in a spreadsheet

Team hours, earlier cash and fewer lapsed rights: the return on alliance management automation

In shortPut in your own numbers. Team time is the part you can measure this month. The value of a right kept is real, and it is a judgment about rare events, so the calculator shows it as an expected value on its own line. Every default here is an assumption.

Event handling, chasing, cash timing and rights kept, each with its formula

Your yearly value from a tracked alliance book

The defaults are round assumptions, and the 48 working weeks are too. The sample book in Part B is one company; it is no benchmark. Set the rights line to zero if you prefer a case that rests on measured time alone.

Is your alliance book ready for automated milestone tracking? Eight questions, scored

In shortScore 0 to 2 on each question, for a total out of 16. The ninth question is for reflection. Your band tells you whether to build the baseline first, run a pilot or plan the whole book.

Explore, pilot or implement: what each score asks of an alliance team

Questions that test an alliance management software vendor on clauses, amendments, clocks and events

In shortAsk these of anyone, including us. Each one comes with what a strong answer sounds like and a warning sign. Bring your own heavily amended agreement to the meeting, because sample contracts are written to work.

Test milestone tracking on one amended license and last year's events before you commit

In shortMeasure first, then test on documents you already know the answers to, then run alongside your current process for one quarter, then decide. You can stop after any step, and no step ties you to a vendor.

1. Write down your baseline: on-time rate over 12 months, and days from event to first action on your last ten events.
2. Build one answer key by hand: one heavily amended license, with every duty, clause in force and owner, checked by counsel.
3. Test on a copy: give the tool the documents and last year's events, with a planted amendment and a planted false alarm.
4. Run in parallel for one quarter on live events, with your people deciding and your normal process still sending notices.
5. Decide with three numbers: duties found against your key, false alarms per true event, and days from event to tested trigger.

What to measure in a milestone tracking pilot

Milestone payments and alliance management, answered: definitions, clocks, accruals, consent and AI

In shortShort answers to what people search. Each one stands alone. For your own contract or accounts, read the document and ask counsel or your auditor.